Reading BIOA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIOA free→Reading BIOA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIOA free→NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is elevated, and the sector backdrop is a headwind, with BIOA trading below typical compared to sector peers. Peer multiples imply a price about 167% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $20.49. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $20, BIOA's earnings are too small for P/E to mean much; on sales it trades at 76× p/s (29.9× the 3× p/s peer median). That gap is an optionality premium a financial-multiple model can't price — our $9.11 fair value covers only the as-is business, low confidence. Analysts: $36–$62. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 118% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.98x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
2 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.64 → $-0.63 (+1.3% / 30d). 3 raised, 1 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d. 78% of analysts rate Buy.
1 PT revisions / 30d. Avg target 122.2% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 0% of the last 1 guided quarters · -200.0% avg surprise
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$239.
How much price usually moves either way.
On a bad day, this stock has moved -$631.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,307.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
The signal changed to cautious. Risk rose. The sector backdrop fell, indicating a headwind for the company. Earnings quality remains loss-making, and management is stable.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for BIOA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 8, 2026, BioAge Labs, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exch…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$36.00 – $62.00 (median $45.00) · 4 analysts · as of 2026-05-27
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
BIOA BioAge Labs, Inc. | Below typical Show detailsSector percentile: 20 of 100 | expensive | elevated |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 89 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 75 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 68 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 64 of 100 | full | low |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to achieve positive cash flow through operational improvements.
Management is committed to improving net income through strategic initiatives.
Management aims to increase revenue through new product launches and market expansion.
and this Item 7.01, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”). The information contained in Item 2.02, this Item 7.01, and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any…
Entry into a Material Definitive Agreement. On January 21, 2026, BioAge Labs, Inc., a Delaware corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.000…
Results of Operations and Financial Condition. On November 6, 2025, BioAge Labs, Inc. (the “ Company ”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (t…
Results of Operations and Financial Condition. On August 6, 2025, BioAge Labs, Inc. (the “ Company ”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ E…